Stocks Alert: Morgan Stanley (MS), Gilead Sciences Inc. (GILD), Medtronic plc (MDT)

Morgan Stanley (MS) grew with the stock adding 1.46% or $0.63 to close at $43.85 on active trading volume of 9.14M compared its three months average trading volume of 12.05M. The New York New York 10036 based company operating under the Investment Brokerage – National industry has been trending up for the last 52 weeks, with the shares price now 55.02% up for the period and up by 3.79% so far this year. With price target of $42.02 and a 111.06% rebound from 52-week low, Morgan Stanley has plenty of upside potential, making it a hold with a view buy.

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals worldwide. The company’s Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides sales and trading services, such as sales, financing, and market-making services in equity securities and fixed income products, including foreign exchange and commodities, as well as prime brokerage services; and corporate lending services, credit products, and investments and research services. Its Wealth Management segment offers various financial services and solutions covering brokerage and investment advisory services, market-making services in fixed income securities, financial and wealth planning services, annuity and insurance products, credit and other lending products, and banking and retirement plan services to individual investors, small-to-medium sized businesses, and institutions. The company’s Investment Management segment provides various investment strategies and products comprising asset management, including equity, fixed income, liquidity, alternatives, and managed futures products. This segment is also involved in merchant banking and real estate investing businesses. Morgan Stanley was founded in 1924 and is headquartered in New York, New York.

Gilead Sciences Inc. (GILD) dropped $-0.52 to close the day at a new closing price of $75.49, a -0.68% decrease in value from its previous closing price that moved the stock 7.27% above its 52 week low of $70.83. A total of 8.97M shares exchanged hands during the day compared with its three month average trading volume of 9.61M. The stock, which fluctuated between $75.41 and $76.5 during the day, currently situated -25.44% below its 52 week high. The stock is up by 4.84% in the past one month and down by -0.31% over the past three months. With a one year target estimate of $95.19 and RSI of 57.61, the stock still has upside potential, making it a hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Medtronic plc (MDT) shares were up in last trading by 2.88% to $72.87. It experienced higher than average volume on day. The stock increased in value by almost 1.86% over the past week and grew 1.66% in the past month. It is currently trading -3.94% below its 50 day moving average and -10.27% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -17.88% decrease in value from its one year high of $89.27. The RSI indicator value of 47.16, lead us to believe that it is a hold for now.

Medtronic plc manufactures and sells device-based medical therapies worldwide. The company’s Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators and cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular intervention products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment provides gastrointestinal diagnostics, ablation, and interventional lung solutions; stapling, vessel sealing, and other surgical instruments; sutures; electrosurgery products; hernia mechanical devices; mesh implants; products for patient monitoring and recovery; sensors; monitors; compression and dialysis, enteral feeding, and wound care products; and operating room supplies, electrodes, needles, syringes, and sharps disposals. The company’s Restorative Therapies Group segment offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, throat, and neurological disorders; systems that incorporate advanced energy surgical instruments; products for haemostatic sealing of soft tissue and bone; and image-guided surgery and intra-operative imaging systems. Its Diabetes Group segment provides insulin pumps and consumables; continuous glucose monitoring systems; and Web-based therapy management software solutions. It serves hospitals, physicians, clinicians, and patients. Medtronic plc was founded in 1949 and is headquartered in Dublin, Ireland.

 

Stocks Alert: Marathon Petroleum Corporation (MPC), Gilead Sciences Inc. (GILD), Hewlett Packard Enterprise Company (HPE)

Marathon Petroleum Corporation (MPC) retreated with the stock falling -0.37% or $-0.19 to close at $51.05 on active trading volume of 9.53M compared its three months average trading volume of 6.24M. The Findlay Ohio 45840 based company operating under the Oil & Gas Refining & Marketing industry has been trending up for the last 52 weeks, with the shares price now 8.66% up for the period and up by 1.39% so far this year. With price target of $56.15 and a 81.06% rebound from 52-week low, Marathon Petroleum Corporation has plenty of upside potential, making it a hold with a view buy.

Marathon Petroleum Corporation, together with its subsidiaries, engages in refining, marketing, retailing, and transporting petroleum products primarily in the United States. It operates through three segments: Refining & Marketing, Speedway, and Midstream. The company refines crude oil and other feed stocks at its seven refineries in the Gulf Coast and Midwest regions of the United States; and purchases ethanol and refined products for resale. Its refined products include gasoline, distillates, propane, feed stocks and special products, heavy fuel oil, and asphalt. The company also sells transportation fuels and convenience products in the retail market through Speedway convenience stores; and transports crude oil and other feed stocks to its refineries and other locations. Marathon Petroleum Corporation markets its refined products to resellers, consumers, independent retailers, wholesale customers, marathon-branded independent entrepreneurs, its Speedway convenience stores, airlines, transportation companies, and utility companies, as well as exports its refined products. As of December 31, 2015, it owned, leased, and had ownership interests in approximately 8,400 miles of crude oil and refined product pipelines, as well as owned and operated 2,766 gasoline and convenience stores in 22 states of the United States; and had 5,600 retail outlets operated by independent entrepreneurs in 19 states in the United States. The company was incorporated in 2009 and is headquartered in Findlay, Ohio.

Gilead Sciences Inc. (GILD) dropped $-0.37 to close the day at a new closing price of $76.01, a -0.48% decrease in value from its previous closing price that moved the stock 8% above its 52 week low of $70.83. A total of 9.41M shares exchanged hands during the day compared with its three month average trading volume of 9.59M. The stock, which fluctuated between $75.57 and $76.85 during the day, currently situated -24.93% below its 52 week high. The stock is up by 5.72% in the past one month and down by -1.38% over the past three months. With a one year target estimate of $95.19 and RSI of 61.12, the stock still has upside potential, making it a hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Hewlett Packard Enterprise Company (HPE) shares were up in last trading by 0.47% to $23.56. It experienced lighter than average volume on day. The stock increased in value by almost 1.12% over the past week and fell -2.43% in the past month. It is currently trading 1.38% above its 50 day moving average and 15.51% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -4.71% decrease in value from its one year high of $24.79. The RSI indicator value of 52.56, lead us to believe that it is a hold for now.

Hewlett Packard Enterprise Company provides technology solutions to business and public sector enterprises. It operates through Enterprise Group, Software, Enterprise Services, and Financial Services segments. The Enterprise Group segment offers industry standard servers and mission-critical servers to address the array of its customers’ computing needs; converged storage solutions, including 3PAR StoreServ, StoreOnce, all-flash arrays, and software defined and StoreVirtual products; wireless local area network equipment, mobility and security software, switches, routers, and network management products; and support and technology consulting services. The Software segment offers software to capture, store, explore, analyze, protect, and share information and insights within and outside organizations; HP Vertica, an analytics database technology for machine, structured, and semi-structured data; and HP IDOL, an analytics tool for human information, as well as solutions for archiving, data protection, eDiscovery, information governance, and enterprise content management. This segment also provides application delivery management, enterprise security, and IT operations management software products. The Enterprise Services segment offers technology consulting, outsourcing, and support services in infrastructure, applications, and business process domains within traditional and strategic enterprise service (SES) offerings, which include analytics and data management, security, and cloud services. The Financial Services segment provides leasing, financing, IT consumption and utility programs, and asset management services. The company markets and sells its products through resellers, distribution partners, original equipment manufacturers, independent software vendors, systems integrators, and advisory firms. Hewlett Packard Enterprise Company is headquartered in Palo Alto, California.

 

Eye Catching Stocks: Wells Fargo & Company (WFC), Rite Aid Corporation (RAD), Gilead Sciences Inc. (GILD)

Wells Fargo & Company (WFC) continued its upward trend with the stock climbing 0.09% or $0.05 to close the day at $56.05 on light trading volume of 15.03M shares, compared to its three month average trading volume of 27.73M. The San Francisco California 94104 based company has been outperforming the money center banks group over the past 52 weeks, with the stock gaining 9.38%, compared to the industry which has dropped -1.56% over the same period. With RSI of 63.46, the stock should still continue to rise and get closer to its one year target estimate of $55.8, making it a hold for now.

Wells Fargo & Company provides retail, commercial, and corporate banking services to individuals, businesses, and institutions. Its Community Banking segment offers checking, savings, market rate, individual retirement, and health savings accounts, as well as time deposits and remittances; and lines of credit, auto floor plan lines, equity lines and loans, equipment and transportation loans, education and residential mortgage loans, and debit and credit cards. This segment also provides equipment leases, real estate and other commercial financing, small business administration financing, venture capital financing, cash management, payroll services, retirement plans, and merchant payment processing and private label financing solutions, as well as purchases retail installment contracts. Its Wholesale Banking segment offers commercial loans and lines of credit, letters of credit, asset-based lending, equipment leasing, international trade facilities, trade financing, collection, foreign exchange, treasury management, investment management, institutional fixed-income sales, interest rate, commodity and equity risk management, insurance, corporate trust fiduciary and agency, and investment banking services, as well as online/electronic products. This segment also provides construction, and land acquisition and development loans; secured and unsecured lines of credit; interim financing arrangements; rehabilitation loans; affordable housing loans and letters of credit; loans for securitization; commercial real estate loan servicing; and real estate and mortgage brokerage services. The company’s Wealth, Brokerage and Retirement segment offers financial advisory, wealth management, brokerage, retirement, trust, and reinsurance services. As of February 25, 2015, it operated through approximately 8,700 locations and 12,500 ATMs & offices in 36 countries. Wells Fargo & Company was founded in 1852 and is headquartered in San Francisco, California.

Rite Aid Corporation (RAD) climbed 1.1% during last trading as the stock added $0.09 to finish the day at $8.27 with about 15.03M shares changing hands, compared to its three month average trading volume of 17.14M. The $8.71B market cap company, which fluctuated between $8.15 and $8.31 during the day, currently situated 30.65% above its 52 week low of $6.33 and -4.83% away from its one year high of $8.69. The RSI of 59.37 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Rite Aid Corporation, through its subsidiaries, operates a chain of retail drugstores in the United States. The company operates through two segments, Retail Pharmacy and Pharmacy Services. The Retail Pharmacy Segment sells prescription drugs; and a range of other merchandises, such as over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other everyday and convenience products. It also operates retail clinics that provide treatment for common conditions; and a range of preventive services, including screenings, medical tests, immunizations, and basic physical exams. In addition, this segment provides health coaching, shared decision making tools, and health care analytics, including health coaching for medical decisions, chronic conditions, and wellness; population analytic solutions; and consulting services. The Pharmacy Services Segment provides pharmacy benefit management (PBM) services and a range of pharmacy-related services. It also offers integrated mail-order and specialty pharmacy services; and performs prescription adjudication services for other PBMs. Rite Aid Corporation has a strategic alliance with GNC. As of February 27, 2016, the company operated approximately 4,561 stores in 31 states of the United States and in the District of Columbia. Rite Aid Corporation was founded in 1927 and is headquartered in Camp Hill, Pennsylvania.

Gilead Sciences Inc. (GILD) saw its value increase by 2.99% as the stock gained $2.22 to finish the day at a closing price of $76.38. The stock was higher in trading and has fluctuated between $70.83-$103.1 per share for the past year. The shares, which traded within a range of $74.38 to $76.98 during the day, are down by -0.48% in the past three months and down by -9.79% over the past six months. It is currently trading 4.13% above its 20 day moving average and 3.4% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $95.19 a share over the next twelve months. The current relative strength index (RSI) reading is 63.4. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

 

Stock’s Trend Analysis Report: Huntington Bancshares Incorporated (HBAN), General Motors Company (GM), Gilead Sciences Inc. (GILD)

Huntington Bancshares Incorporated (HBAN) climbed 0.76% during last trading as the stock added $0.1 to finish the day at $13.32 with about 10.92M shares changing hands, compared to its three month average trading volume of 14.18M. The $14.3B market cap company, which fluctuated between $13.22 and $13.52 during the day, currently situated 74.92% above its 52 week low of $7.83 and -1.77% away from its one year high of $13.64. The RSI of 63.9 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Huntington Bancshares Incorporated operates as a holding company for The Huntington National Bank that provides commercial, small business, consumer, and mortgage banking services. The company’s Retail and Business Banking segment offers financial products and services, including checking accounts, savings accounts, money market accounts, certificates of deposit, consumer loans, and small business loans; and investments, insurance, interest rate risk protection, and foreign exchange and treasury management services. Its Commercial Banking segment provides corporate risk management and institutional sales, trading, and underwriting services; commercial property and casualty, employee benefits, personal lines, life and disability, and specialty lines of insurance; and brokerage and agency services for residential and commercial title insurance, as well as excess and surplus product lines of insurance. The company’s Automobile Finance and Commercial Real Estate segment offers financing for the purchase of vehicles; financing the acquisition of new and used vehicle inventory of franchised automotive dealerships; and financing for land, buildings, and other commercial real estate owned or constructed by real estate developers, automobile dealerships, or other customers. Its Regional Banking and The Huntington Private Client Group segment provides deposits, lending, and other banking services; wealth management services, and retirement plan and corporate trust services; and brokerage, annuities, advisory, and other investment products. The company’s Home Lending segment offers consumer loans and mortgages. Huntington Bancshares Incorporated also provides equipment leasing; and online, mobile, and telephone banking services. The company was founded in 1866 and is headquartered in Columbus, Ohio.

General Motors Company (GM) gained $0.31 to close the day at a new closing price of $35.15, a 0.89% increase in value from its previous closing price that moved the stock 38.15% above its 52 week low of $26.69. A total of 10.9M shares exchanged hands during the day compared with its three month average trading volume of 13.77M. The stock, which fluctuated between $34.84 and $35.57 during the day, currently situated -6.86% below its 52 week high. The stock is down by -2.47% in the past one month and up by 10.9% over the past three months. With a one year target estimate of $36.76 and RSI of 50.63, the stock still has upside potential, making it a hold for now.

General Motors Company designs, builds, and sells cars, crossovers, trucks, and automobile parts worldwide. The company operates through GM North America, GM Europe, GM International Operations, GM South America, and GM Financial segments. It markets its vehicles primarily under the Buick, Cadillac, Chevrolet, GMC, Opel, Holden, Vauxhall, Baojun, Jiefang, and Wuling brand names. The company also sells cars and trucks to dealers for consumer retail sales, as well as to fleet customers, including daily rental car companies, commercial fleet customers, leasing companies, and governments. In addition, it offers connected safety, security and mobility solutions, and information technology services. The company, through its subsidiary, General Motors Financial Company, Inc., provides automotive financing services. General Motors Company was founded in 1897 and is based in Detroit, Michigan.

Gilead Sciences Inc. (GILD) had a light trading with around 10.9M shares changing hands compared to its three month average trading volume of 9.48M. The stock traded between $72.18 and $74.23 before closing at the price of $74.16 with 3.56% change on the day. The Foster City California 94404 based company is currently trading 5.38% above its 52 week low of $70.83 and -26.76% below its 52 week high of $103.1. Both the RSI indicator and target price of 54.68 and $95.19 respectively, lead us to believe that it should be put on hold over the coming weeks.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

 

Investor’s Alert: Anthera Pharmaceuticals, Inc. (ANTH), Kinder Morgan, Inc. (KMI), Gilead Sciences Inc. (GILD)

Anthera Pharmaceuticals, Inc. (ANTH) continued its downward trend with the stock declining -4.82% or $-0.03 to close the day at $0.71 on higher than average trading volume of 7.91M shares, compared to its three month average trading volume of 1.46M. The Hayward California 94545 based company has been outperforming the biotechnology companies by -77.2201% for last three months and its recent losses have pulled the stock down -84.78% YTD, versus the biotechnology industry which is up 2.11% for the same period. The RSI of 25.76 indicates the stock is oversold at the current levels, buy for now.

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The company’s Phase III product candidates include liprotamase or Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, and others. It also develops Blisibimod, which is in Phase II clinical study for the treatment of Immunoglobulin A nephropathy. The company was founded in 2004 and is headquartered in Hayward, California.

Kinder Morgan, Inc. (KMI) had a active trading with around 7.7M shares changing hands compared to its three month average trading volume of 14.92M. The stock traded between $20.71 and $20.9 before closing at the price of $20.76 with 0.14% change on the day. The Houston Texas 77002 based company is currently trading 90.59% above its 52 week low of $11.2 and -10.6% below its 52 week high of $23.36. Both the RSI indicator and target price of 45.48 and $25.22 respectively, lead us to believe that it should be put on hold over the coming weeks.

Kinder Morgan, Inc. operates as an energy infrastructure company in North America. It operates through Natural Gas Pipelines, CO2, Terminals, Products Pipelines, Kinder Morgan Canada, and Other segments. The Natural Gas Pipelines segment owns and operates interstate and intrastate natural gas pipeline and storage systems; natural gas and crude oil gathering systems, and natural gas processing and treating facilities; natural gas liquids fractionation facilities and transportation systems; and liquefied natural gas facilities. The CO2 segment produces, transports, and markets CO2 for use in enhanced oil recovery projects; and owns interests in oil-producing fields, gas processing plants, and crude oil pipelines in the Permian Basin region of West Texas. The Terminals segment owns and operates liquids and bulk terminals that transload and store refined petroleum products, crude oil, and condensate, as well as bulk products, including coal, petroleum coke, cement, alumina, salt, and other bulk chemicals; and owns and operates tankers. The Products Pipelines segment owns and operates refined petroleum products, and crude oil and condensate pipelines; and associated product terminals and petroleum pipeline transmix facilities. The Kinder Morgan Canada segment owns and operates Trans Mountain pipeline system that transports crude oil and refined petroleum products from Edmonton, Alberta, and Canada to marketing terminals and refineries in British Columbia, Canada, and Washington; and jet fuel aviation turbine fuel pipeline that serves the Vancouver (Canada) International Airport. The Other segment includes various physical natural gas contracts with power plants. Kinder Morgan, Inc. owns interests in or operates approximately 84,000 miles of pipelines and 180 terminals. The company was formerly known as Kinder Morgan Holdco LLC and changed its name to Kinder Morgan, Inc. in February 2011. Kinder Morgan, Inc. was founded in 1936 and is headquartered in Houston, Texas.

Gilead Sciences Inc. (GILD) traded within a range of $71.94 to $72.85 after opening the day at $72.77. The company has seen its stock decrease in value by -27.07% so far this year. The stock was down close to -0.88% on light volume in last trading session and closed at $72.13 per share. After the recent fall, the stock is currently holding -28.76% below its 52 week high of $103.1 and 2.49% above its 12-month low of $70.83. The shares are down by over -6.76% in the last three months, and the RSI indicator value of 42 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

 

Traders Watch list: Huntington Bancshares Incorporated (HBAN), QUALCOMM Incorporated (QCOM), Gilead Sciences Inc. (GILD)

Huntington Bancshares Incorporated (HBAN) saw its value decrease by -1.41% as the stock dropped $-0.19 to finish the day at a closing price of $13.25. The stock was lighter in trading and has fluctuated between $7.83-$13.64 per share for the past year. The shares, which traded within a range of $13.21 to $13.56 during the day, are up by 34.37% in the past three months and up by 57.77% over the past six months. It is currently trading 1.11% above its 20 day moving average and 11.93% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $13.79 a share over the next twelve months. The current relative strength index (RSI) reading is 62.44.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Huntington Bancshares Incorporated operates as a holding company for The Huntington National Bank that provides commercial, small business, consumer, and mortgage banking services. The company’s Retail and Business Banking segment offers financial products and services, including checking accounts, savings accounts, money market accounts, certificates of deposit, consumer loans, and small business loans; and investments, insurance, interest rate risk protection, and foreign exchange and treasury management services. Its Commercial Banking segment provides corporate risk management and institutional sales, trading, and underwriting services; commercial property and casualty, employee benefits, personal lines, life and disability, and specialty lines of insurance; and brokerage and agency services for residential and commercial title insurance, as well as excess and surplus product lines of insurance. The company’s Automobile Finance and Commercial Real Estate segment offers financing for the purchase of vehicles; financing the acquisition of new and used vehicle inventory of franchised automotive dealerships; and financing for land, buildings, and other commercial real estate owned or constructed by real estate developers, automobile dealerships, or other customers. Its Regional Banking and The Huntington Private Client Group segment provides deposits, lending, and other banking services; wealth management services, and retirement plan and corporate trust services; and brokerage, annuities, advisory, and other investment products. The company’s Home Lending segment offers consumer loans and mortgages. Huntington Bancshares Incorporated also provides equipment leasing; and online, mobile, and telephone banking services. The company was founded in 1866 and is headquartered in Columbus, Ohio.

QUALCOMM Incorporated (QCOM) shares were down in last trading by -2.23% to $65.75. It experienced lighter than average volume on day. The stock decreased in value by almost -1.73% over the past week and fell -2.01% in the past month. It is currently trading -1.96% below its 50 day moving average and 11.86% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -7.48% decrease in value from its one year high of $71.62. The RSI indicator value of 41.97, lead us to believe that it is a hold for now.

QUALCOMM Incorporated develops, designs, manufactures, and markets digital communications products and services in China, South Korea, Taiwan, the United States, and internationally. The company operates through three segments: Qualcomm CDMA Technologies (QCT); Qualcomm Technology Licensing (QTL); and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on code division multiple access (CDMA), orthogonal frequency division multiple access (OFDMA), and other technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses or provides rights to use portions of its intellectual property portfolio, which include various patent rights useful in the manufacture and sale of certain wireless products comprising products implementing CDMA2000, WCDMA, CDMA TDD, and/or LTE standards, as well as their derivatives. The QSI segment invests in early-stage companies in various industries, including digital media, e-commerce, healthcare, and wearable devices for supporting the design and introduction of new products and services for voice and data communications. The company also develops and offers products for implementation of small cells; mobile health products and services; software products, and content and push-to-talk enablement services to wireless operators; and development, and other services and related products to the United States government agencies and their contractors. In addition, it licenses chipset technology and products for data centers. QUALCOMM Incorporated was founded in 1985 and is headquartered in San Diego, California.

Gilead Sciences Inc. (GILD) traded within a range of $72.62 to $73.7 after opening the day at $73.61. The company has seen its stock decrease in value by -26.42% so far this year. The stock was down close to -1.3% on light volume in last trading session and closed at $72.77 per share. After the recent fall, the stock is currently holding -28.13% below its 52 week high of $103.1 and 3.4% above its 12-month low of $70.83. The shares are down by over -7.26% in the last three months, and the RSI indicator value of 44.88 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

 

Stocks in Focus: Bristol-Myers Squibb Company (BMY), Gilead Sciences Inc. (GILD), The Procter & Gamble Company (PG)

Bristol-Myers Squibb Company (BMY) had a active trading with around 5.41M shares changing hands compared to its three month average trading volume of 12.17M. The stock traded between $58.77 and $59.92 before closing at the price of $59.61 with 1.45% change on the day. The New York New York 10154 based company is currently trading 21.58% above its 52 week low of $49.03 and -22.17% below its 52 week high of $77.12. Both the RSI indicator and target price of 71.75 and $62.53 respectively, lead us to believe that it could drop over the coming weeks.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has a clinical trial collaboration with Calithera Biosciences, Inc. to evaluate Opdivo in combination with Calithera’s CB-839 in patients with clear cell renal cell carcinoma. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Gilead Sciences Inc. (GILD) managed to rebound with the stock climbing 0.46% or $0.34 to close the day at $73.64 on light trading volume of 5.31M shares, compared to its three month average trading volume of 9.64M. The Foster City California 94404 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -27.26%, compared to the industry which has dropped -7.56% over the same period. With RSI of 48.44, the stock should still continue to rise and get closer to its one year target estimate of $95.19, making it a hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

The Procter & Gamble Company (PG) shares were up in last trading by 0.58% to $84.96. It experienced lighter than average volume on day. The stock increased in value by almost 0.33% over the past week and grew 2.76% in the past month. It is currently trading 0.34% above its 50 day moving average and 1.5% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -5.22% decrease in value from its one year high of $90.33. The RSI indicator value of 54.14, lead us to believe that it is a hold for now.

The Procter & Gamble Company provides branded consumer packaged goods to consumers in North America, Europe, the Asia Pacific, India, the Middle East, Africa, and Latin America. The company’s Beauty segment offers hair care products comprising conditioners, shampoos, styling aids, and treatments; and antiperspirants and deodorants, personal cleansing, and skin care products. This segment markets its products under the Head & Shoulders, Olay, Pantene, Rejoice, Old Spice, Safeguard, and SK-II brands. Its Grooming segment provides blades and razors, pre- and post-shave products, and other shave care products, as well as appliances under the Braun, Fusion, Gillette, Mach3, Prestobarba, and Venus brands. The company’s Health Care segment offers toothbrushes, toothpaste, and other oral care products; and gastrointestinal, rapid diagnostics, respiratory, vitamins/minerals/supplements, and other healthcare products under the Oral-B, Crest, Prilosec, Vicks, Metamucil, Pepto Bismol, and Align brands. Its Fabric & Home Care segment provides fabric care products, including fabric enhancers, laundry additives, and laundry detergents; and home care products comprising air care, dish care, P&G professional, and surface care products under the Tide, Ariel, Downy, Gain, Cascade, Dawn, Febreze, Mr. Clean, and Swiffer brands. The company’s Baby, Feminine & Family Care segment offers baby care products, such as baby wipes, diapers, and pants; adult incontinence and feminine care products; and family care products, such as paper towels, tissues, and toilet papers. This segment markets its products under the Pampers, Always, Bounty, Charmin, Luvs, and Tampax brands. The company sells its products through mass merchandisers, grocery stores, membership club stores, drug stores, department stores, distributors, baby stores, specialty beauty stores, e-commerce, high-frequency stores, and pharmacies. The Procter & Gamble Company was founded in 1837 and is based in Cincinnati, Ohio.

 

Stocks Intraday Alert: Gilead Sciences Inc. (GILD), Oclaro, Inc. (OCLR), Cliffs Natural Resources Inc. (CLF)

Gilead Sciences Inc. (GILD) continued its downward trend with the stock declining -0.89% or $-0.66 to close the day at $73.3 on lower than average trading volume of 8.4M shares, compared to its three month average trading volume of 9.64M. The Foster City California 94404 based company has been underperforming the biotechnology companies by -9.3195% for last three months and its recent losses have pulled the stock down -25.89% YTD, versus the biotechnology industry which is up 5.48% for the same period. The RSI of 47.04 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Oclaro, Inc. (OCLR) had a active trading with around 8.31M shares changing hands compared to its three month average trading volume of 5.22M. The stock traded between $9.48 and $10.07 before closing at the price of $9.55 with 0.32% change on the day. The San Jose California 95131 based company is currently trading 202.22% above its 52 week low of $3.16 and -6.28% below its 52 week high of $10.19. Both the RSI indicator and target price of 59.14 and $12.19 respectively, lead us to believe that it should be put on hold over the coming weeks.

Oclaro, Inc. designs, manufactures, and markets lasers and optical components, modules, and subsystems for the optical communications, industrial, and consumer laser markets worldwide. The company’s products generate, detect, combine, and separate light signals in optical communications networks. It offers client side transceivers, including pluggable transceivers; line side transceivers; tunable laser transmitters, such as discrete lasers and co-packaged laser modulators; lithium niobate modulators to manipulate the phase or the amplitude of an optical signal; transponder modules for transmitter and receiver functions; and discrete lasers and receivers for metro and long-haul applications. The company markets its products through direct sales force, as well as through sales representatives and resellers. It serves network equipment manufacturers of telecommunications and datacom systems, and hyperscale data center operators. The company was formerly known as Bookham, Inc. and changed its name to Oclaro, Inc. in April 2009. Oclaro, Inc. was founded in 1988 and is headquartered in San Jose, California.

Cliffs Natural Resources Inc. (CLF) traded within a range of $8.81 to $9.26 after opening the day at $9.06. The company has seen its stock increase in value by 465.19% so far this year. The stock was down close to -2.72% on light volume in last trading session and closed at $8.93 per share. After the recent fall, the stock is currently holding -18.07% below its 52 week high of $10.9 and 644.17% above its 12-month low of $1.2. The shares are up by over 45.44% in the last three months, and the RSI indicator value of 50.05 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Cliffs Natural Resources Inc., a mining and natural resources company, produces and supplies iron ore. The company operates five iron ore mines in Michigan and Minnesota; and Koolyanobbing iron ore mining complex located in Western Australia, which produces lump and fines iron ore. It also own two iron ore mines in Eastern Canada. Cliffs Natural Resources Inc. sells its iron products to integrated steel companies and steel producers in the United States, China, Canada, and internationally. The company was formerly known as Cleveland-Cliffs Inc. Cliffs Natural Resources Inc. was founded in 1847 and is headquartered in Cleveland, Ohio.

 

Stocks To Watch: The Charles Schwab Corporation (SCHW), W&T Offshore, Inc. (WTI), Gilead Sciences Inc. (GILD)

The Charles Schwab Corporation (SCHW) traded within a range of $39.71 to $40.19 after opening the day at $40.13. The company has seen its stock increase in value by 22.58% so far this year. The stock was down close to -0.42% on light volume in last trading session and closed at $39.98 per share. After the recent fall, the stock is currently holding -0.45% below its 52 week high of $40.19 and 87.17% above its 12-month low of $21.51. The shares are up by over 28.25% in the last three months, and the RSI indicator value of 67.41 is neither bullish nor bearish, tempting investors to stay on the sidelines.

The Charles Schwab Corporation, through its subsidiaries, provides wealth management, securities brokerage, banking, money management, custody, and financial advisory services. The company operates through two segments, Investor Services and Advisor Services. The Investor Services segment provides retail brokerage and banking services, retirement plan services, and other corporate brokerage services; and stock plan services, compliance solutions, and mutual fund clearing services, as well as engages in the off-platform sales business. The Advisor Services segment provides custodial, trading, and support services; and retirement and corporate brokerage retirement services. The company provides brokerage accounts with cash management capabilities; third-party mutual funds through the Mutual Fund Marketplace, including no-transaction fee mutual funds through the Mutual Fund OneSource service, which includes proprietary mutual funds, plus mutual fund trading, and clearing services to broker-dealers; exchange-traded funds (ETFs), including proprietary and third-party ETFs; and advice solutions, such as managed portfolios of proprietary and third-party mutual funds and ETFs, separately managed accounts, customized personal advice for tailored portfolios, and specialized planning and portfolio management. It also offers banking products and services, including checking and savings accounts, certificates of deposit, first lien residential real estate mortgage loans, home equity loans and lines of credit, and Pledged Asset Lines; and trust services comprising trust custody services, personal trust reporting services, and administrative trustee services. The company serves individuals and institutional clients in the United States, the Commonwealth of Puerto Rico, London, and Hong Kong. The Charles Schwab Corporation was founded in 1971 and is headquartered in San Francisco, California.

W&T Offshore, Inc. (WTI) failed to extend gains with the stock declining -3.96% or $-0.12 to close the day at $2.91 on active trading volume of 7.03M shares, compared to its three month average trading volume of 1.63M. The Houston Texas 77406 based company has been outperforming the oil & gas drilling & exploration group over the past 52 weeks, with the stock gaining 39.9%, compared to the industry which has advanced 65.66% over the same period. With RSI of 75.24, the stock should still continue to rise and get closer to its one year target estimate of $2.55, making it a hold for now.

W&T Offshore, Inc., an independent oil and natural gas producer, engages in the acquisition, exploration, and development of oil and natural gas properties in the Gulf of Mexico. The company sells crude oil, natural gas liquids, and natural gas. It holds working interests in approximately 54 offshore fields in federal and state waters. As of March 8, 2016, the company had interests in offshore leases covering approximately 900,000 gross acres, including approximately 550,000 gross acres in the Gulf of Mexico Shelf; and approximately 350,000 gross acres in the deepwater. It also has a total proved reserves of 76.4 million barrels of oil equivalent. The company was founded in 1983 and is headquartered in Houston, Texas.

Gilead Sciences Inc. (GILD) dropped $-0.09 to close the day at a new closing price of $73.96, a -0.12% decrease in value from its previous closing price that moved the stock 5.09% above its 52 week low of $70.83. A total of 6.98M shares exchanged hands during the day compared with its three month average trading volume of 9.75M. The stock, which fluctuated between $73.56 and $74.83 during the day, currently situated -27.17% below its 52 week high. The stock is down by -0.73% in the past one month and down by -8.69% over the past three months. With a one year target estimate of $95.47 and RSI of 50.68, the stock still has upside potential, making it a hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

 

Stocks Intraday Alert: Morgan Stanley (MS), Bonanza Creek Energy Inc. (BCEI), Gilead Sciences Inc. (GILD)

Morgan Stanley (MS) continued its upward trend with the stock climbing 1.56% or $0.67 to close the day at $43.5 on higher than average trading volume of 8.62M shares, compared to its three month average trading volume of 12.54M. The New York New York 10036 based company has been outperforming the investment brokerage – national companies by 36.7904% for last three months and its recent gains have pushed the stock slightly up 40.1% YTD, versus the investment brokerage – national industry which is up 28.12% for the same period. The RSI of 71.88 indicates the stock is overbought at the current levels, sell for now.

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals worldwide. The company’s Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides sales and trading services, such as sales, financing, and market-making services in equity securities and fixed income products, including foreign exchange and commodities, as well as prime brokerage services; and corporate lending services, credit products, and investments and research services. Its Wealth Management segment offers various financial services and solutions covering brokerage and investment advisory services, market-making services in fixed income securities, financial and wealth planning services, annuity and insurance products, credit and other lending products, and banking and retirement plan services to individual investors, small-to-medium sized businesses, and institutions. The company’s Investment Management segment provides various investment strategies and products comprising asset management, including equity, fixed income, liquidity, alternatives, and managed futures products. This segment is also involved in merchant banking and real estate investing businesses. Morgan Stanley was founded in 1924 and is headquartered in New York, New York.

Bonanza Creek Energy Inc. (BCEI) had a active trading with around 8.57M shares changing hands compared to its three month average trading volume of 2.1M. The stock traded between $2.04 and $2.34 before closing at the price of $2.23 with 18.62% change on the day. The Denver Colorado 80202 based company is currently trading 271.67% above its 52 week low of $0.6 and -63.68% below its 52 week high of $6.14. Both the RSI indicator and target price of 83.62 and $1.02 respectively, lead us to believe that it could drop over the coming weeks.

Bonanza Creek Energy Inc., an independent energy company, engages in the acquisition, exploration, development, and production of onshore oil and associated liquids-rich natural gas in the United States. The company’s oil and liquids weighted assets are located primarily in the Wattenberg Field in Colorado; and the Dorcheat Macedonia Field in southern Arkansas. It also owns and operates oil-producing assets in the North Park Basin in Colorado; and the McKamie Patton Field in Southern Arkansas. Bonanza Creek Energy Inc. was founded in 2010 and is headquartered in Denver, Colorado.

Gilead Sciences Inc. (GILD) traded within a range of $73.43 to $74.63 after opening the day at $74.51. The company has seen its stock decrease in value by -25.13% so far this year. The stock was down close to -0.47% on light volume in last trading session and closed at $74.05 per share. After the recent fall, the stock is currently holding -27.08% below its 52 week high of $103.9 and 5.22% above its 12-month low of $70.83. The shares are down by over -8.78% in the last three months, and the RSI indicator value of 50.9 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.